Featured News

Does living with celiac disease impact your daily life? We need your help to advance celiac disease research and test an investigational medication.  

Is celiac disease holding you back? If so, consider joining the FB102-301 study for people who have celiac disease who are currently on a gluten-free diet. The phase 2 FB102-301 study is researching a potential new…

Is celiac disease having a significant impact on your daily life? You may be eligible for a clinical study. The ASPIRION study is a phase 2 study looking into a new, investigational study drug (amlitelimab) for patients with celiac disease.

New Phase 2 Clinical Trial: TEV-CeD2 Study

The ILLUMINATE-101 Study is a phase 2 clinical research study evaluating the safety and effectiveness of an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease.

The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.

The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.

ImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe…

Cour Pharmaceuticals has announced a $420 million licensing deal with Takeda Pharmaceuticals following a favorable outcome of their phase 2 trial for celiac disease. The company released data from a…

On August 13th, 2019, Innovate Biopharmaceuticals, Inc. (Innovate) announced the first patient has been dosed in its Phase 3 clinical trial for patients with celiac disease. The CeD LA 3001…